Australia's most trusted
source of pharma news
Saturday, 27 April 2024
Posted 1 July 2022 AM
In a double win Bayer has secured funding for its pan-tumour therapy Vitrakvi along with a genetic test needed to consider eligibility for treatment.
Vitrakvi has been provisionally approved in Australia since September 2020 for patients with locally advanced or metastatic solid tumours that have a NTRK fusion.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.